Simplified Dosing of Gentamicin for Treatment of Sepsis in Bangladeshi Neonates by Hossain, M. Monir et al.
©INTERNATIONAL CENTRE FOR DIARRHOEAL
DISEASE RESEARCH, BANGLADESH
J HEALTH POPUL NUTR  2009 Oct;27(5):640-645
ISSN 1606-0997 | $ 5.00+0.20
Simplified Dosing of Gentamicin for Treatment of 
Sepsis in Bangladeshi Neonates
M. Monir Hossain1, Nazma A. Chowdhury1, Mahfuza Shirin1, Samir K. Saha2, Mary Miller-Bell3, 
David Edwards4,5, Jacob Aranda5, Patricia Coffey6, and Gary L. Darmstadt7
1Department of Neonatology and 2Department of Microbiology, Bangladesh Institute of Child Health, Dhaka Shishu (Children’s) 
Hospital, Dhaka 1207, Bangladesh, 3Department of Pharmacology, Duke University, Durham, NC, USA, 4Department of 
Pharmacy Practice, Wayne State University, Detroit, MI, USA, 5NIH/NICHD Pediatric Pharmacology Research Unit Network, 
Children’s Hospital of Michigan, Wayne State University, Detroit, MI, USA, 6PATH, Seattle, WA, USA, and 7International Center 
for Advancing Neonatal Health, Department of International Health, Bloomberg School of Medicine, Johns Hopkins University, 
Baltimore, MD 21205, USA
ABSTRACT
Extended-interval dosing of gentamicin has several advantages over conventional multiple-daily dosing 
for the treatment of sepsis. The study was conducted to evaluate the pharmacokinetics of gentamicin for 
the treatment of neonatal sepsis in predetermined doses at 24- or 48-hour intervals, according to weight 
category, and to develop a simplified protocol for use in peripheral healthcare settings in developing coun-
tries. This prospective observational study was conducted among 59 neonates admitted to the Special Care 
Nursery at Dhaka Shishu Hospital, Bangladesh, with suspected sepsis and treated with antibiotics, includ-
ing gentamicin. Intravenous dosing of gentamicin according to weight category was: 10 mg every 48 hours 
if the infant weighed <2,000 g (n=23), 10 mg every 24 hours if the infant weighed 2,000-2,249 g (n=12), or 
13.5 mg every 24 hours if the infant weighed 2,500-3,000 g (n=24). Peak and trough concentrations of gen-
tamicin and the presence of signs of nephrotoxicity and ototoxicity were determined. The mean±standard 
deviation peak concentration of gentamicin was 12.3±3.7 µg/mL in infants weighing <2,000 g, 9.6±3.1 
µg/mL in infants 2,000-2,249 g, and 10.0±3.4 µg/mL in infants 2,500-3,000 g. Initial peak concentration 
of gentamicin was >12 µg/mL in 28.8% and initial trough concentration was >2 µg/mL in 6.8% of the 
subjects. No signs of nephrotoxicity or ototoxicity were detected. Favourable pharmacokinetic parameters 
found with the simplified dosing regimen suggest that it is safe for the treatment of neonatal sepsis. 
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INTRODUCTION
An estimated 20% of all children born in develop-
ing countries acquire an infection during the neo-
natal period, and infectious diseases account for ap-
proximately one-third of all neonatal deaths (1,2). 
Many neonatal deaths can be averted if the signs 
of infection could be recognized early by caregiv-
ers and first-line health workers and the disease is 
treated promptly (3-8).
Gentamicin is a potent aminoglycoside antibiotic 
with bactericidal activity against Gram-negative 
bacteria. Among the causative agents of neonatal 
sepsis, Gram-negative pathogens play a crucial role, 
and gentamicin is the drug of choice for first-line 
management. On the basis of the large volumes 
of distribution and slow renal clearance of ami-
noglycosides in neonates, larger doses based on 
body-weight, administered at longer intervals, are 
advantageous (9-12). To treat neonatal sepsis more 
effectively in low-resource settings, it is necessary to 
develop a strategy for extended-interval dosing of Hossain MM et al. Gentamicin dosing in neonates
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gentamicin, i.e. 24 hours or more in between doses 
since more frequent contact with a health worker 
is often not feasible.  
Based on the evidence that extended-interval dos-
ing of gentamicin has many advantages over more 
frequent-interval dosing regimens, we aimed at 
evaluating extended-interval dosing regimens for 
gentamcin, which were developed based on issues 
of pharmacokinetics, safety, frequency of dosing, 
body-weight of the patient, and acceptability as 
described previously (13,14). Here, we report phar-
macokinetic and safety evaluation results from the 
Bangladesh site of a two-site study reported else-
where (13).
MATERIALS AND METHODS
Patients
The study was conducted in Dhaka Shishu (Chil-
dren’s) Hospital, a major medical centre for chil-
dren in South Asia, in the Neonatal Special Care 
Nursery where out-born neonates are admitted. 
We initially aimed at enrolling 20 patients weigh-
ing <2,000 g, 10 patients weighing 2,000-2,240 g, 
and 20 patients weighing 2,500-3,000 g with guid-
ance on total enrollment from the study’s Data 
Safety Monitoring Board, which regularly reviewed 
progress of the trial, with an aim to ensure safety of 
patients. Neonates up to 28 days of age, who were 
admitted from 15 February to 15 June 2003 for the 
treatment of suspected or culture-proven neonatal 
sepsis, were included in the study (Fig.). Neonates 
with major congenital anomalies, haemodynamic 
instability, or compromised renal function were 
excluded. Once a potential participant was identi-
fied, a parent was counselled in the presence of a 
senior staff nurse, and informed written consent 
was obtained. The Ethical Review Committee at 
the Bangladesh Institute of Child Health, the Com-
mittee on Human Research at the Johns Hopkins 
Bloomberg School of Public Health, and the PATH 
Human Subjects Protection Committee approved 
the protocol. All unexpected adverse events were 
reported to the appropriate authorities within 24 
hours. The study was registered at clinicaltrials.gov 
(#H.22.02.08.30.B1).
Gentamicin-dosing and monitoring
All patients received standard clinical management 
of sepsis, which included use of additional antibio-
tics in combination with gentamicin to provide 
broad-spectrum coverage as indicated based on 
available clinical and laboratory data. Neonates 
were enrolled into different weight categories and 
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received a fixed dose and frequency of administra-
tion of gentamicin specific for each weight category 
(Fig. and Table). The rationale for selection of these 
dosing-interval regimens has been reported previ-
ously (13,14). Patients weighing 2,250-2,499 g were 
not included in the study because extended-inter-
val dosing regimens of gentamicin, which reliably 
produce favourable pharmacokinetics, are already 
available, and further testing was, thus, not war-
ranted.
The dose was pushed intravenously over a 30-sec-
ond period, followed by a flush with 0.5 mL of nor-
mal saline. For monitoring trough concentrations 
of gentamicin, blood was obtained 30 minutes pri-
or to the administration of the third dose, and the 
peak level was monitored in serum separated from 
blood collected one hour after the administration 
of the third dose. Since renal excretion of gentami-
cin is slower in low-birthweight (LBW) babies, the 
safety of administration in patients with very LBW, 
weighing <2,000 g was further ensured by giving 
the doses only at 48-hour intervals. The monitor-
ing strategy for these babies was modified so that 
the serum level of drug was available as early as pos-
sible. Thus, serum levels were obtained 2 and 24 
hours after the first dose of gentamicin rather than 
the trough and peak levels around the third dose as 
for patients weighing >2,000 g. Serum levels of gen-
tamicin were measured by chemiluminescent assay 
with Immulite 2000 (Diagnostic Products Corpora-
tion, Los Angeles, CA). Pharmacokinetic indices, 
including peak and trough levels of genatmicin, 
were determined as described previously (13). 
For infants weighing >2,000 g, whenever abnor-
mal gentamicin trough levels were detected, i.e. 
>2 µg/mL, the dosing-interval was extended from 
24 to 48 hours. If the peak concentration was >12 
µg/mL, the dose was decreased by 10-15%, and if 
the peak was <4 µg/mL, the dose was increased by 
10-15%. Whenever dose modifications were made, 
repeat gentamicin levels were determined 48 hours 
later.
Blood samples were collected from 23, 12, and 24 
patients in the three weight categories: <2,000 g, 
2,000-2,249 g, and 2,500-3,000 g respectively. Hae-
moglobin concentration, serum electrolytes, plas-
ma creatinine, and urine output were monitored 
during the study period. All the enrolled patients 
were followed up once for hearing assessment be-
tween 6 and 12 weeks of age. Hearing assessment 
was done by Brainstem Auditory Evoked Response 
(BAER) testing.
RESULTS
Of the 59 patients, 30 (51%) were preterm (<37 
completed weeks of gestation), 46 (78%) were 
male, and 29 (49%) were aged one day. Duration of 
hospital stay was 2-22 days (mean±standard devia-
tion 8.6±4.2 days). Culture-positive septicaemia was 
identified in 10.1% (6/59) of the cases. The isolated 
organisms were Escherichia coli (n=2), Klebsiella pneu-
moniae (n=1), Staphylococcus aureus (n=1), Salmonella 
spp. (n=1), and Haemophilus influenzae (n=1). Total 
doses of gentamicin given to patients across the 
three weight categories ranged from 1 to 10, and 
the duration of treatment was 2-10 days (Table).
Initial peak concentrations of gentamicin were >12 
µg/mL and <4 µg/mL in 28.8% and 1.7% of the 
patients respectively (Table). Initial trough concen-
tration was ≥2.0 µg/mL in 6.8% of the cases. Nine-
teen (32.2%) neonates required adjustment of gen-
tamicin dose; nine were in the category of <2,000 g 
and five each were in the categories of 2,000-2,249 
g and 2,500-3,000 g. Nine patients each weighing 
<2,000 g had a high peak level; none had a high 
trough level. In the category of 2,000-2,249 g, ad-
justment of dose was needed for three patients for 
high peak, one for high trough, and one for low 
Table. Pharmacokinetics of gentamicin by neonatal weight category
Pharmacokinetic parameter
Weight category
<2,000 g
(n=23)
2,000-2,249 g 
(n=12)
2,500-3,000 g 
(n=24)
Dosage of gentamicin (mg) 10 10 13.5
Interval of dose (hours) 48 24 24
Number of doses  1-6  3-10  2-10 
Days of treatment   2-10  3-10  2-10 
Peak concentration (mean±SD, μg/mL) 12.1±3.6 9.6±3.1 9.7±2.9
Trough concentration (mean±SD, μg/mL) 0.4±0.4 1.6±1.3 1.4±1.2
SD=Standard deviationHossain MM et al. Gentamicin dosing in neonates
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peak. Five (24.0%) patients in the group of 2,500-
3,000 g needed correction; two for both high peak 
and trough serum concentrations, and three for 
high peak concentration only. 
On enrollment, plasma creatinine level was normal 
(<120 µmol/L) in 91.4% (53/58) of the patients. At 
the time of discharge, all the patients, except one 
(serum creatinine level 169 µmol/L), including the 
cases with elevated serum gentamicin peak and/or 
trough levels, had normal plasma creatinine levels. 
The frequency of urine output was also normal in 
98.3% (57/58) of the cases.
Seven patients died, none of whom had an abnor-
mal serum level of gentamicin. Causes of death 
included prematurity with septicaemia (n=2), birth 
asphyxia with septicaemia (n=2), and birth asphyx-
ia (n=3). Three patients left against medical advice, 
and two of them had an abnormal level of gentam-
icin. Two patients (5%; 2/40) were labelled as im-
paired for hearing on assessment at 6-12 weeks of 
age. However, gentamicin levels of all these cases 
were normal (peak 8.9 µg/mL to 9.7 µg/mL, trough 
0.1 µg/mL to 2.0 µg/mL).
DISCUSSION
This study evaluated the dosing of gentamicin at an 
interval of 24-48 hours in different weight groups, 
considering pharmacokinetics and safety. Studies 
have shown that pharmacokinetics of gentamicin 
are essentially equivalent following intravenous 
and intramuscular injections (15). The results of 
this study, which involved intravenous administra-
tion, can be extrapolated to intramuscular injec-
tions, the suitable mode to use in the community, 
including peripheral health facilities, where intra-
venous access is not available. 
Pharmacokinetic data of gentamicin indicate that 
half-lives are longer in neonates compared to older 
children (16-18). These data lend support to the 
recommendation to increase the dosing-interval 
from 12 to 18 hours up to 24 hours or more. There 
has been recent interest in extended (e.g. daily or 
less frequent) dosing of aminoglycosides because 
higher doses given at longer intervals are likely 
to improve efficacy and reduce the toxic effects 
(9,12,14). In a developing country like Bangladesh, 
once-daily dosing of gentamicin can be used as 
an important treatment option in neonatal sepsis 
whereas more frequent dosing is not feasible for 
use in the community and peripheral health-facili-
ty settings (14,19). 
In our study, the mean peak concentrations around 
the third dose in patients weighing 2,000-2,249 g 
and 2,500-2,999 g were consistent with other stud-
ies of once-daily dosing of gentamicin (9,11,12,20-
22). Skopnik compared two groups of neonates who 
received once- and twice-daily doses of gentamicin 
and found that the once-daily group did better re-
garding efficacy and toxicity (21). High peak con-
centration of aminoglycoside is the major determi-
nant of bacterial killing rather than the minimum 
inhibitory concentration of the antibiotic (23,24). 
The target peak concentration of gentamicin is 4-
12 µg/mL (25) but 29% (17/59) of the cases in this 
study had higher peak values (range 12.1-20.6 µg/
mL). Nonetheless, all the cases had normal renal 
function as measured by plasma creatinine level. 
Further, hearing assessment of 12 of the cases at 6-
12 weeks of age did not reveal any sign of ototox-
icity attributable to antibiotic exposure. This is in 
accordance with previous findings about the safety 
of higher peak levels of gentamicin (25). 
Pharmacokinetic data of gentamicin administra-
tion in neonates with very low birthweight indicate 
that the elimination half-life is longer in preterm 
compared to full-term neonates (26). Thus, we fixed 
the initial dose for preterm babies with very low 
birthweight as 10 mg given every 48 hours. In this 
weight category, we found a high peak concentra-
tion (>12 µg/mL) in more than one-third (39.1%) 
of the babies, although their trough concentrations 
were uniformly normal. Evidence would suggest 
that the dose used in this weight category will be ef-
ficacious (14), and since trough levels were normal, 
this dose is acceptable. 
A low trough concentration of <2 µg/mL is a de-
sirable goal because aminoglycosides exhibit a 
marked post-antibiotic effect (persistent suppres-
sion of microbial growth after antmicrobial drug 
exposure ceases), and longer duration of low lev-
els helps prevent the rapid development of mi-
crobial resistance (adaptive resistance) and mini-
mizes nephrotoxicity and ototoxicity (27). In the 
present study, the mean trough concentrations of 
gentamicin in all the three weight categories were 
acceptable. The distributions of trough levels were 
the same as reported in previous studies where 
gentamicin was given once or twice daily at doses 
of 4-5 mg/kg of body-weight per day (9-12,14,21). 
Our findings are consistent with those of Hayani et 
al. who showed that trough concentration is not 
increased if a larger dose is given at a prolonged in-
terval (9). Nephrotoxicity is one of the recognized 
complications of aminoglycoside therapy. Clinical 
studies have shown that renal toxicity is less fre-
quent in newborns (28,29); this is due, in part, to 
the lower rate of renal accumulation of gentamicin Hossain MM et al. Gentamicin dosing in neonates
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in neonates (28). In the present study, we had only 
one neonate with raised plasma creatinine; how-
ever, the infant had normal peak (11.2 µg/mL) and 
trough (0.1 µg/mL) levels of gentamicin. Mulhall 
et al. showed that the incidence of nephrotoxicity 
is reduced when the dosing interval is >18 hours 
in neonates (25). Ototoxicity is another potential 
complication of gentamicin therapy. Hearing as-
sessment at 6-12 weeks revealed only two infants 
with hearing impairments. However, this did not 
appear to be attributable to gentamicin therapy as 
none of the cases had any abnormality in peak and 
trough levels of gentamicin. 
In conclusion, this study of extended-interval dos-
ing of gentamicin, stratified for different weight 
categories of neonates, indicates that this dosing 
scheme is simple, adequate, safe, and feasible for 
the treatment of neonatal sepsis in communities 
and peripheral health facilities. Such dosages are 
now being manufactured in pre-filled Uniject™ 
(Becton Dickinson) devices and used for the evalu-
ation of safety and acceptability for the treatment 
of neonatal sepsis at the community level. 
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